HUTCHMED (China) Limited (Stock Code: 00013) presented its 2025 full-year results and key business updates. According to the announcement, the company reported a net income of US$456.90 million, reflecting profitable core operations and gains from non-core divestments. Consolidated revenue for 2025 was US$548.50 million, down 13% year-on-year.

In-market sales of Fruzaqla (fruquintinib ex-China) grew by 26% to US$366.20 million, driven by geographical expansion and new reimbursements. Elunate (fruquintinib in China) recorded in-market sales of US$100.10 million, while Orpathys (savolitinib) triggered an US$11.00 million milestone payment from its collaboration partner for additional approval in China. Meanwhile, the company’s next-generation Antibody-Targeted Therapy Conjugates (ATTC) platform advanced its first two drug candidates into global clinical trials last year.

The 2025 financial statements also highlighted R&D expenses of US$148.30 million, with continued investment in key programs. The company’s disposal of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited for approximately US$608.50 million bolstered its liquidity, leading to a year-end cash balance of US$1.37 billion.

According to the announcement, HUTCHMED plans continued enhancements of its commercial operations in China and further global expansions, with several approvals, filings, and trial readouts anticipated. The company underscored its sustainability performance with notable ESG ratings, as well as ongoing initiatives in climate risk assessments and governance improvements. It expects to publish its full Sustainability Report and 2025 Annual Report in April 2026.